1
|
Desmurget C, Frentzel J, Strembitska A, Sobkowiak K, Perilleux A, Souquet J, Borth N, Douet J. Combined approach of selective and accelerated cloning for microfluidic chip-based system increases clone specific productivity. Biotechnol J 2024; 19:e2300488. [PMID: 38803036 DOI: 10.1002/biot.202300488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Revised: 05/03/2024] [Accepted: 05/07/2024] [Indexed: 05/29/2024]
Abstract
Improving current cell line development workflows can either focus on increasing the specific productivity of the cell lines or shortening timelines to reach the clinic as fast as possible. In this work, using the Beacon platform, we have combined two distinct protocols - early cloning with low-viability pools, and IgG membrane staining-, to concomitantly reach both objectives, and generate highly productive CHO clones in shorter timelines. Fast-sorting approaches using low-viability pools in combination with the Beacon platform have recently been reported to shorten CLD timelines. However, the low recovery led to a drastic reduction in the clone number obtained postcloning. Here, we report a combined approach of fast-sorting and fluorescent membrane staining. With this new protocol, the cells reach a correct recovery, allowing to fully exploit the Beacon screening capacities. In addition, by using a fluorescent staining recognizing the secreted IgG, we were able to enrich the fraction of highly secreting cells prior to cloning and we obtained significant increases in the cell's specific productivity. The combination of these two protocols has a synergistic effect, and as they help discarding the dead and nonproducing populations prior to cloning, they increase the throughput power of the Beacon platform and the detection of super productive clones.
Collapse
Affiliation(s)
- Caroline Desmurget
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| | - Julie Frentzel
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| | - Anastasiya Strembitska
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| | - Katarzyna Sobkowiak
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| | - Arnaud Perilleux
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| | - Jonathan Souquet
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| | - Nicole Borth
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Julien Douet
- Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland
| |
Collapse
|
2
|
Diep J, Le H, Le K, Zasadzinska E, Tat J, Yam P, Zastrow R, Gomez N, Stevens J. Microfluidic chip-based single-cell cloning to accelerate biologic production timelines. Biotechnol Prog 2021; 37:e3192. [PMID: 34323013 PMCID: PMC9285370 DOI: 10.1002/btpr.3192] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 07/06/2021] [Accepted: 07/12/2021] [Indexed: 12/20/2022]
Abstract
Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability.
Collapse
Affiliation(s)
- Jonathan Diep
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Huong Le
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Kim Le
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Ewelina Zasadzinska
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Jasmine Tat
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Pheng Yam
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Ryan Zastrow
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Natalia Gomez
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| | - Jennitte Stevens
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA
| |
Collapse
|
3
|
Louie S, Heidersbach A, Blanco N, Haley B, Rose CM, Liu PS, Yim M, Tang D, Lam C, Sandoval WN, Shaw D, Snedecor B, Misaghi S. Endothelial intercellular cell adhesion molecule 1 contributes to cell aggregate formation in CHO cells cultured in serum‐free media. Biotechnol Prog 2020; 36:e2951. [DOI: 10.1002/btpr.2951] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 11/14/2019] [Accepted: 12/11/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Salina Louie
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Amy Heidersbach
- Molecular Biology DepartmentGenentech, Inc. South San Francisco California
| | - Noelia Blanco
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Benjamin Haley
- Molecular Biology DepartmentGenentech, Inc. South San Francisco California
| | - Christopher M. Rose
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - Peter S. Liu
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - Mandy Yim
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Danming Tang
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Cynthia Lam
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Wendy N. Sandoval
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - David Shaw
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Brad Snedecor
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Shahram Misaghi
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| |
Collapse
|
4
|
Welch JT, Arden NS. Considering “clonality”: A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development. Biologicals 2019; 62:16-21. [DOI: 10.1016/j.biologicals.2019.09.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/13/2019] [Accepted: 09/16/2019] [Indexed: 12/23/2022] Open
|
5
|
Mitigating Clonal Variation in Recombinant Mammalian Cell Lines. Trends Biotechnol 2019; 37:931-942. [DOI: 10.1016/j.tibtech.2019.02.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 02/14/2019] [Accepted: 02/19/2019] [Indexed: 12/27/2022]
|
6
|
Pekle E, Smith A, Rosignoli G, Sellick C, Smales CM, Pearce C. Application of Imaging Flow Cytometry for the Characterization of Intracellular Attributes in Chinese Hamster Ovary Cell Lines at the Single-Cell Level. Biotechnol J 2019; 14:e1800675. [PMID: 30925020 DOI: 10.1002/biot.201800675] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 01/21/2019] [Indexed: 11/07/2022]
Abstract
Biopharmaceutical manufacturing using Chinese hamster ovary (CHO) cells requires the generation of high-producing clonal cell lines. During cell line development, cell cloning using fluorescence-activated cell sorting (FACS) has the potential to combine isolation of single cells with sorting based on specific cellular attributes that correlate with productivity and/or growth, identifying cell lines with desirable phenotypes for manufacturing. This study describes the application of imaging flow cytometry (IFC) to characterize recombinant cell lines at the single-cell level to identify cell attributes predictive of productivity. IFC assays are developed to quantify the organelle content and recombinant heavy-chain (HC) and light-chain (LC) polypeptide as well as messenger RNA (mRNA) amounts in single cells. The assays are then validated against orthogonal standard flow cytometry, western blot, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) methods. The authors describe how these IFC assays may be used in cell line development and show how cellular properties can be correlated with productivity at the single-cell level, allowing the isolation of such cells during the cloning process. From the analysis, HC polypeptide and mRNA are found to be predictive of productivity early in the culture; however, specific organelle content did not show any correlation with productivity.
Collapse
Affiliation(s)
- Eva Pekle
- MedImmune, Granta Park, Cambridge, CB21 6GH, UK.,Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK
| | | | | | | | - C M Smales
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK
| | | |
Collapse
|
7
|
Lee JS, Park JH, Ha TK, Samoudi M, Lewis NE, Palsson BO, Kildegaard HF, Lee GM. Revealing Key Determinants of Clonal Variation in Transgene Expression in Recombinant CHO Cells Using Targeted Genome Editing. ACS Synth Biol 2018; 7:2867-2878. [PMID: 30388888 DOI: 10.1021/acssynbio.8b00290] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Generation of recombinant Chinese hamster ovary (rCHO) cell lines is critical for the production of therapeutic proteins. However, the high degree of phenotypic heterogeneity among generated clones, referred to as clonal variation, makes the rCHO cell line development process inefficient and unpredictable. Here, we investigated the major genomic causes of clonal variation. We found the following: (1) consistent with previous studies, a strong variation in rCHO clones in response to hypothermia (33 vs 37 °C) after random transgene integration; (2) altered DNA sequence of randomly integrated cassettes, which occurred during the integration process, affecting the transgene expression level in response to hypothermia; (3) contrary to random integration, targeted integration of the same expression cassette, without any DNA alteration, into three identified integration sites showed the similar response of transgene expression in response to hypothermia, irrespective of integration site; (4) switching the promoter from CMV to EF1α eliminated the hypothermia response; and (5) deleting the enhancer part of the CMV promoter altered the hypothermia response. Thus, we have revealed the effects of integration methods and cassette design on transgene expression levels, implying that rCHO cell line generation can be standardized through detailed genomic understanding. Further elucidation of such understanding is likely to have a broad impact on diverse fields that use transgene integration, from gene therapy to generation of production cell lines.
Collapse
Affiliation(s)
- Jae Seong Lee
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
| | - Jin Hyoung Park
- Department of Biological Sciences, KAIST, 291 Daehak-ro,
Yuseong-gu, Daejeon 305-701, Republic of Korea
| | - Tae Kwang Ha
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Mojtaba Samoudi
- Department of Pediatrics, University of California, San Diego, La Jolla, California 92093, United States
- The Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego School of Medicine, La Jolla, California 92093, United States
| | - Nathan E. Lewis
- Department of Pediatrics, University of California, San Diego, La Jolla, California 92093, United States
- The Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego School of Medicine, La Jolla, California 92093, United States
- Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States
| | - Bernhard O. Palsson
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
- Department of Pediatrics, University of California, San Diego, La Jolla, California 92093, United States
- Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States
| | - Helene Faustrup Kildegaard
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Gyun Min Lee
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
- Department of Biological Sciences, KAIST, 291 Daehak-ro,
Yuseong-gu, Daejeon 305-701, Republic of Korea
| |
Collapse
|
8
|
Hunter M, Yuan P, Vavilala D, Fox M. Optimization of Protein Expression in Mammalian Cells. ACTA ACUST UNITED AC 2018; 95:e77. [DOI: 10.1002/cpps.77] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
9
|
Le K, Tan C, Gupta S, Guhan T, Barkhordarian H, Lull J, Stevens J, Munro T. A novel mammalian cell line development platform utilizing nanofluidics and optoelectro positioning technology. Biotechnol Prog 2018; 34:1438-1446. [PMID: 30009534 PMCID: PMC6585769 DOI: 10.1002/btpr.2690] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 06/26/2018] [Accepted: 06/27/2018] [Indexed: 12/21/2022]
Abstract
Generating a highly productive cell line is resource intensive and typically involves long timelines because of the need to screen large numbers of candidates in protein production studies. This has led to miniaturization and automation strategies to allow for reductions in resources and higher throughput. Current approaches rely on the use of standard cell culture vessels and bulky liquid handling equipment. New nanofludic technologies offer novel solutions to surpass these limits, further miniaturizing cell culture volumes (105 times smaller) by growing cells on custom nanofluidic chips. Berkeley Lights' OptoElectro Positioning technology projects light patterns to activate photoconductors that gently repel cells to manipulate single cells on nanofluidic culturing chips. Using a fully integrated technology platform (Beacon), common cell culture tasks can be programmed through software, allowing maintenance and analysis of thousands of cell lines in parallel on a single chip. Here, we describe the ability to perform key cell line development work on the Beacon platform. We demonstrate that commercial production Chinese hamster ovary cell lines can be isolated, cultured, screened, and exported at high efficiency. We compare this process head to head with a FACS-enabled microtiter plate-based workflow and demonstrate generation of comparable clonal cell lines with reduced resources. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1438-1446, 2018.
Collapse
Affiliation(s)
- Kim Le
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Christopher Tan
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Shivani Gupta
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Trupti Guhan
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Hedieh Barkhordarian
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Jonathan Lull
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Jennitte Stevens
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Trent Munro
- Attribute Sciences, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| |
Collapse
|
10
|
Ko P, Misaghi S, Hu Z, Zhan D, Tsukuda J, Yim M, Sanford M, Shaw D, Shiratori M, Snedecor B, Laird M, Shen A. Probing the importance of clonality: Single cell subcloning of clonally derived CHO cell lines yields widely diverse clones differing in growth, productivity, and product quality. Biotechnol Prog 2017; 34:624-634. [DOI: 10.1002/btpr.2594] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 11/14/2017] [Indexed: 01/08/2023]
Affiliation(s)
- Peggy Ko
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Shahram Misaghi
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Zhilan Hu
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Dejin Zhan
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Joni Tsukuda
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Mandy Yim
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Mark Sanford
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - David Shaw
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Masaru Shiratori
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Brad Snedecor
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Michael Laird
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Amy Shen
- Early Stage Cell Culture (ESCC) Dept.; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| |
Collapse
|
11
|
Shaw D, Yim M, Tsukuda J, Joly JC, Lin A, Snedecor B, Laird MW, Lang SE. Development and characterization of an automated imaging workflow to generate clonally-derived cell lines for therapeutic proteins. Biotechnol Prog 2017; 34:584-592. [DOI: 10.1002/btpr.2561] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 09/14/2017] [Indexed: 11/09/2022]
Affiliation(s)
- David Shaw
- Early Stage Cell Culture, Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Mandy Yim
- Early Stage Cell Culture, Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Joni Tsukuda
- Early Stage Cell Culture, Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - John C. Joly
- Analytical Development and Quality Control; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Andy Lin
- Pharma Technical Development Project and Portfolio Management; Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Brad Snedecor
- Early Stage Cell Culture, Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Michael W. Laird
- Early Stage Cell Culture, Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| | - Steven E. Lang
- Early Stage Cell Culture, Genentech, Inc., 1 DNA Way; South San Francisco CA 94080
| |
Collapse
|
12
|
Zhou Y, Shaw D, Lam C, Tsukuda J, Yim M, Tang D, Louie S, Laird MW, Snedecor B, Misaghi S. Beating the odds: The poisson distribution of all input cells during limiting dilution grossly underestimates whether a cell line is clonally-derived or not. Biotechnol Prog 2017; 34:559-569. [PMID: 28941017 DOI: 10.1002/btpr.2560] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 09/20/2017] [Indexed: 11/12/2022]
Abstract
Establishing that a cell line was derived from a single cell progenitor and defined as clonally-derived for the production of clinical and commercial therapeutic protein drugs has been the subject of increased emphasis in cell line development (CLD). Several regulatory agencies have expressed that the prospective probability of clonality for CHO cell lines is assumed to follow the Poisson distribution based on the input cell count. The probability of obtaining monoclonal progenitors based on the Poisson distribution of all cells suggests that one round of limiting dilution may not be sufficient to assure the resulting cell lines are clonally-derived. We experimentally analyzed clonal derivatives originating from single cell cloning (SCC) via one round of limiting dilution, following our standard legacy cell line development practice. Two cell populations with stably integrated DNA spacers were mixed and subjected to SCC via limiting dilution. Cells were cultured in the presence of selection agent, screened, and ranked based on product titer. Post-SCC, the growing cell lines were screened by PCR analysis for the presence of identifying spacers. We observed that the percentage of nonclonal populations was below 9%, which is considerably lower than the determined probability based on the Poisson distribution of all cells. These results were further confirmed using fluorescence imaging of clonal derivatives originating from SCC via limiting dilution of mixed cell populations expressing GFP or RFP. Our results demonstrate that in the presence of selection agent, the Poisson distribution of all cells clearly underestimates the probability of obtaining clonally-derived cell lines. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 34:559-569, 2018.
Collapse
Affiliation(s)
- Yizhou Zhou
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - David Shaw
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Cynthia Lam
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Joni Tsukuda
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Mandy Yim
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Danming Tang
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Salina Louie
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Michael W Laird
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Brad Snedecor
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| | - Shahram Misaghi
- Early Stage Cell Culture (ESCC) Department, Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080
| |
Collapse
|
13
|
Klottrup KJ, Miro-Quesada G, Flack L, Pereda I, Hawley-Nelson P. Measuring the aggregation of CHO cells prior to single cell cloning allows a more accurate determination of the probability of clonality. Biotechnol Prog 2017; 34:593-601. [PMID: 28556621 DOI: 10.1002/btpr.2500] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 05/14/2017] [Indexed: 11/11/2022]
Abstract
The manufacturing process for biotherapeutics is closely regulated by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory agencies worldwide. To ensure consistency of the product of a manufacturing cell line, International Committee on Harmonization guidelines (Q5D, 1997) state that the cell substrate should be derived from a single cell progenitor, i.e., clonal.Cell lines in suspension culture may naturally revert to cell adhesion in the form of doublets, triplets and higher order structures of clustered cells. We can show evidence of a single colony from limiting dilution cloning or in semi-solid media, but we cannot determine the number of cells from which the colony originated. To address this, we have used the ViCELL® XR (Beckman Coulter, High Wycombe, UK) cell viability analyzer to determine the proportion of clusters of two or more cells in a sample of the cell suspension immediately prior to cloning. Here, we show data to define the accuracy of the ViCELL for characterizing a cell suspension and summarize the statistical model combining two or more rounds of cloning to derive the probability of clonality. The resulting statistical model is applied to cloning in semi-solid medium, but could equally be applied to a limiting dilution cloning process. We also describe approaches to reduce cell clusters to generate a cell line with a high probability of clonality from a CHO host lineage. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 34:593-601, 2018.
Collapse
Affiliation(s)
- Kerensa J Klottrup
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, MedImmune, Cambridge, CB21 6GH, UK
| | - Guillermo Miro-Quesada
- Data Management and Quantitative Sciences, Biopharmaceutical Development, MedImmune, Gaithersburg, MD, 20878
| | | | - Ivan Pereda
- R&D Informatics, AstraZeneca, Cambridge, CB21 6GH, UK
| | - Pamela Hawley-Nelson
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, MedImmune, Gaithersburg, MD, 20878
| |
Collapse
|